Immunotherapy for autologous/syngeneic peripheral blood stem cell (PBSC) transplant patients as treatment for advanced multiple myeloma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interferon alpha; Interleukin-2; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2017 Biomarkers information updated
- 29 Feb 2012 Last checked against ClinicalTrials.gov record.
- 29 Feb 2012 Planned end date (Jun 2060) added as reported by ClinicalTrials.gov.